Form 4: Director John B. Henneman III Receives Orthofix Stock Grant

Director John B. Henneman III was granted 14,965 deferred stock units by Orthofix Medical Inc. as part of an equity award.

Summary

• Director John B. Henneman III acquired 14,965 deferred stock units (DSUs) on June 10, 2026.
• The DSUs were granted at a price of $0 per unit.
• Following this transaction, the director's total beneficial ownership increased to 105,774 shares.
• The award vests in full on the first anniversary of the grant date, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with shareholders through increased equity ownership.
• Standard equity-based compensation structure for board members.

Negatives

• None identified.

Risks

• Vesting is subject to the reporting person's continued service through the first anniversary of the grant date.

Future Outlook

The deferred stock units will vest on June 10, 2027, and will settle into common stock within 45 days of the director's termination of service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the medical device industry to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant structure is consistent with standard director compensation packages for mid-cap medical technology companies.
• The use of deferred stock units is a common retention and alignment tool used by peers such as Zimmer Biomet or NuVasive.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Vesting of the 14,965 deferred stock units on June 10, 2027.

Key Dates

Keywords

Orthofix Medical, OFIX, Form 4, Insider Transaction, Director Compensation, Equity Grant